Introduction
In the discovery phase of drug development, in vivo pharmacology experiments in animals are commonly used alongside in vitro experiments to screen for efficacy and early detection of activity. In the area of epilepsy, several nonclinical pharmacology models are available, which generally involve the application of a chemical or electrical stimulus to invoke seizures in rodents. The ability of an investigative drug to prevent these seizures is then observed. In an effort to facilitate the discovery of new antiepilepsy drugs (AEDs), the National Institutes of Health (NIH) runs an anticonvulsant screening program, 1 where submitted potential anticonvulsants undergo a list of screening tests in various animal seizure models. Two commonly used in vivo nonclinical pharmacology seizure models in the NIH program -the pentylenetetrazole seizure (PTZ) model and the maximal electroshock seizure (MES) model -have been in use for decades and are currently still in use. In the PTZ model, the convulsant chemical pentylenetetrazole is injected subcutaneously into the rodent to produce clonic seizures. The ability of a test compound at different pretreatment doses/times to raise the seizure threshold and protect the animal from exhibiting a clonic seizure is observed, usually for 30 min after injection of PTZ. With the MES seizure model, an alternating current is delivered through corneal electrodes to induce a seizure in rodents. Seizure 24 (2015) [21] [22] [23] [24] [25] [26] [27] Again, the ability of a test compound at different pretreatment doses/times to prevent the spread of seizure discharge and protect the animal from exhibiting hindlimb tonic seizures is observed. PTZ models are often associated with absence seizures whilst MES models are associated with general tonic-clonic seizures. In both models, a dose that inhibits maximal response by 50% (ED50) is often calculated from these experiments.
We have previously shown that photosensitive proof of principle trials in human can predict human antiepileptic efficacy, 2 and therefore can be a useful tool in drug development. Prior to first human dose testing, data from animal pharmacology models already available can potentially be used to inform and predict exposures in humans required for efficacy. The aim of this research was to evaluate whether preclinical seizure models -specifically the PTZ and MES rodent models -can be early predictors of human exposures required for antiepileptic efficacy. This was performed through a survey of current literature reporting ED50 results from commonly prescribed AEDs.
Materials and methods
In order to streamline the list of AEDs, only those that presented with good evidence of efficacy were selected according to the International League Against Epilepsy (ILAE) treatment guidelines. 3 Drugs with the highest levels of evidence for efficacy The human and rodent plasma clearance (CL) values for each AED were obtained from the FDA approved drug labels, FDA reviews, or literature. [4] [5] [6] [7] [8] [9] [10] [11] [12] Since mice pharmacokinetics were not commonly reported, mouse clearance where unavailable was scaled down from rat clearance using simple allometry principles with the following equation:
The standard weights used for the allometric scaling calculations for mice, rat and human were 0.025, 0.25 and 70 kg, respectively. Ratios of AUC at human MED to AUC at rodent ED50 were calculated. These ratios were described by summary statistics and exposure comparisons were summarised graphically.
Results
A total of 1274 articles were identified in the literature search across different combinations of search terms as described in the methods section. Of these, 27 articles were found to contain information on ED50 in PTZ models, 67 in MES models, and 27 in both models.
107-133 Table 1 shows the mean and variability of the ED50s in mice and rat PTZ and MES models reported across the various literature papers for the nine AEDs investigated. Generally, there were fewer articles describing experiments in rats compared to mice, and more articles were found describing MES than PTZ models. ED50 values for the PTZ model ranged from approximately 10 mg/kg to 600 mg/kg across the nine AEDs investigated, and PHT and CBZ were not effective in this model. In the MES model, the ED50 values Table 1 when at least 50% of the articles found for that particular AED reported an ED50 value. The comparison of AUC ratios at human MED to rodent ED50 are shown in Table 2 . The results show that across the nine AEDs investigated, the average [standard deviation (sd)] ratio of exposures at human MED to mice ED50 was 1.4 (3.9) for the PTZ model and 3.8 (3.1) for the MES model. There was less information available in rats compared to mice, but ratios were similar with a range of 1-2 for rat in the PTZ model and average (sd) of 4.1 (2.1) in the MES model. CBZ and OXC appeared to be outliers, therefore summary statistics were also calculated without these two AEDs. Comparison of human exposures at MED and rodent exposures at ED50 in the PTZ and MES models across the various AEDs are summarised graphically in Fig. 1. 
Discussion
This literature survey investigated whether PTZ and MES rodent seizure models can quantitatively predict human exposures efficacious in epilepsy, by comparing the exposure in human efficacious doses versus the exposures at ED50 in the rodent PTZ and MES models. The results showed that the ratios of human exposures at MEDs to rodent exposures at ED50 in both PTZ and MES models were close to 1 (mean of approximately 1.5 and 4 for PTZ and MES, respectively). Thus, both these rodent seizure models can be useful tools in early drug development.
The PTZ model performed slightly better than the MES model with a ratio closer to 1 and with a mixture of over and underpredictions across the nine AEDs selected. The MES model, on the other hand, tended to consistently under-predict human exposures/doses required for efficacy, resulting in mean ratios of approximately 4 for both mice and rat. This consistent underprediction could be due to the way the experiments were conducted, where ED50s were obtained at a single time point when peak effect of the particular AED was observed. In humans, although peak effect is important, maintaining efficacy over the entire dosing interval is equally important to prevent any breakthrough seizures when AED concentrations are at trough levels. Thus, it is also important to conduct time course experiments in rodents to obtain ED50s when AED concentrations are lower, and to observe if there are any delays between peak Human AUC showing avera ge and ra nge of maintenan ce do ses Mou se AUC at ED50 Rat AUC at ED50 Fig. 1 . AUC exposures at human MED and approved dose ranges and at ED50 in the mice and rat PTZ and MES models for different AEDs. concentrations of AED and peak anti-seizure effect. Pharmacokinetic/pharmacodynamic modelling techniques can often be useful in these instances, with various examples already found in literature including the modelling of anticonvulsant action of phenobarbital in rats 134 and the correlation of various AEDs in the cortical stimulation model. 135 These models can be used to provide a more robust and conservative estimate of human efficacious exposures and/or doses. The PTZ and MES models seemed to perform equally well across drugs with different mechanisms of action. Of the nine drugs investigated, four potentiate gamma-aminobutyric acid (GABA) inhibition (GBP, PB, VB and VPA), four modulate voltagedependent sodium/calcium channels (CBZ, LTG, OXC and PHT) and TPM has mixed mechanisms. The ratios of human MED to rodent ED50 exposures did not appear to be different across all these compounds with different mechanisms of action, with the exception of CBZ and OXC, which showed the highest ratios. The reasons for these findings are unknown, however it is interesting that CBZ and OXC are related analogues. Further investigation into exposure ratios for Eslicarbazepine, another related analogue to CBZ, may help resolve this trend. Nevertheless, it is encouraging that the PTZ and MES models show efficacy and predictability into humans across AEDs with different mechanisms of actions.
False negatives were present in both rodent models, with PHT and CBZ not showing efficacy in the PTZ model but good efficacy in the MES model. There tended to be fewer false negatives in the MES model with only VGB not showing efficacy in the MES model but efficacy in the PTZ model. Given these false negatives, potential antiepileptic compounds should not be screened solely against one single model but to be tested across a few different seizure models. This literature survey pre-selected efficacious human AEDs, thus it would not have captured true negative cases or false positive cases in using the PTZ or MES models to predict human efficacy.
Although the AUC ratio was closer to 1 for the PTZ model, the higher AUC ratio for the MES model was associated with lower variability, and therefore if a correction factor (of approximately 4) was applied, human dose predictions with better precision could be obtained with the MES model instead. However these analyses were done with only nine AEDs and more AEDs should be added in order for a more robust correction factor to be calculated and used. Besides, the aim of early human dose predictions is to evaluate the feasibility of dosing up to predicted efficacious doses in humans in a safe manner consistent with known toxicology data. In practice, a wide range of human doses will be explored in Phase 1 clinical trials beyond these predicted efficacious doses, which make the precision of the predicted dose less important than its mean value at this stage of drug development. A general recommendation from these analyses could be to use the MES model in efficacy screening for compound prioritisation since there have been fewer false negatives with this method, but to use the PTZ model for human dose prediction calculations (along with acknowledgement of the uncertainty involved). Although there was generally no difference between rat and mice AUC ratios in each seizure model, more data was available for mice compared to rat and therefore whilst both species could be used equally, caution should be used when interpreting data from rats. If comparisons against values in literature were to be made, then more information is available in mice.
In conclusion, both the rodent PTZ and MES seizure models can reasonably predict human efficacious doses and exposures in epilepsy, and could be used as tools in screening and prioritisation of compounds in early drug discovery. Early accurate predictions of human efficacious doses (together with all the other information generated at the preclinical stage), allow better risk/benefit assessment of whether to carry forward the compound into the next stage of development, which is invariably more costly and time consuming.
